By: Tom Sellig, Chief Executive Officer, Adare Pharma Solutions
As drug development grows more complex and timelines compress, sponsors require CDMO relationships built on integration, flexibility, and shared accountability
The relationship between pharmaceutical sponsors and their CDMO partners has undergone a fundamental transformation. Not long ago, CDMOs were largely treated as capacity providers that executed a defined scope, then stepped aside. Today, the most successful partnerships look nothing like that. They are deeply embedded collaborations in which both parties are genuinely invested in outcomes, from early formulation through commercial launch and beyond.
Moving Beyond the Handoff Model
Several converging forces have made the traditional handoff-based outsourcing model increasingly obsolete. Supply chain volatility—driven by pandemic aftershocks, tariff pressures, inflation, and transportation bottlenecks—has exposed the fragility of fragmented provider networks. At the same time, therapies themselves have grown more complex, demanding tighter coordination between formulation science, process design, regulatory strategy, and commercial manufacturing. In a capital-constrained environment where timelines are compressing, sponsors cannot afford the delays, rework, and miscommunication that arise when multiple vendors operate in silos.
The CDMO landscape is responding accordingly. Consolidation is accelerating as organizations that lack the infrastructure, scalability, or operational discipline to keep pace fall behind. The partners that are emerging as leaders share a common profile: differentiated technology platforms, global manufacturing footprints, and integrated end-to-end service offerings.
The Case for End-to End Integration
Working with a single, fully integrated CDMO from early development through commercial manufacturing and packaging delivers measurable advantages. Consistency across the program lifecycle reduces handoff risk. Teams that are involved from the outset understand scale-up considerations, process constraints, and quality requirements before they become problems. Technical leads and project managers who stay with a program from start to finish maintain institutional knowledge that simply cannot be replicated when work is parceled out among multiple providers.
At Adare Pharma Solutions, we have built our operating model around this philosophy. Our integrated capabilities span formulation development, clinical and commercial manufacturing, and packaging, with specialization in oral solid dosage forms like tablets, capsules, multiparticulates, orally disintegrating tablets, and sprinkle formulations. Our manufacturing network has facilities in both the United States and Europe to give sponsors regional access and supply chain resilience across the world’s two largest pharmaceutical markets. We have successfully manufactured more than 65 products across this network, and that experience is reflected in every aspect of how we operate.
Culture as a Competitive Advantage
What ultimately distinguishes a true strategic partner is culture: the habits, behaviors, and values that determine how an organization responds when plans change, challenges arise, or timelines shift. And the most effective culture is one built around the customer, fostering open communication, faster problem-solving, and proactive risk management. A customer-focused culture means every customer is paired with a dedicated project manager, cross-functional teams stay aligned throughout each program, and potential issues are flagged before they become obstacles.
I challenge our teams every day to find creative ways to be faster, safer, and more cost-effective for our customers. This continuous-improvement mentality is what turns a contractual relationship into a genuine partnership.
Meeting Tomorrow’s Challenges Today
The trajectory is clear. As programs move faster and grow more complex, sponsors will place even greater importance on CDMO partners that align formulation, manufacturing, and packaging from the outset. The CDMOs that thrive will be those that combine operational excellence, technological innovation, and an unwavering commitment to their customers’ success. In the end, the principle is simple: when your CDMO cares about your success as much as you do, that is a true strategic partnership.
About the Author:
Tom Sellig has more than 30 years of global experience in the life sciences industry, including experience scaling organizations and driving growth in the CDMO and Pharma Services space.
From 2019 to 2021 Tom served as Chief Executive Officer of LabConnect, a clinical trial laboratory services organization. Under his leadership, the company more than doubled in revenue and underwent significant team expansion to meet the growing needs of the biopharma industry.
Prior to LabConnect, Tom was Chief Commercial Officer at ConnectiveRx, where he was responsible for all commercial and customer-facing activity at the patient support and patient access company. Earlier, Tom was Senior Vice President of Global Sales at Patheon, where he played an integral role in the company’s sale to and integration with Thermo Fisher. Previously, he served as the Global Vice President of Sales and Client Services at Covance. Tom received his bachelor’s degree in Economics from Vanderbilt University and an MBA from New York University.